Uncertainty and Possible Subclinical Valve Leaflet Thrombosis.

Transcatheter aortic-valve replacement (TAVR) has had a profound effect on the management of structural heart disease, as evidenced by the fact that since 2010 the Journal has featured six reports on pivotal registries or randomized TAVR trials.16 The effect can also be assessed by the incredible growth in the number of procedures. The Transcatheter Valve Therapy Registry, launched by the Society of Thoracic Surgeons and the American College of Cardiology, has enrolled approximately 35,000 patients who have been treated with commercially approved devices at 376 centers in 49 states in the United States alone. The rapid growth of this . . .